Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Shares of Japanese pharma major Daiichi Sankyo soared 14.4% to 4,095 yen by close of Tokyo trading today, after it announced what, if all goes according to plan, could be the biggest pharma licensing deal ever seen. 20 October 2023
Biotechnology
Osaka, Japan-based biotech RegCell today announced the appointment of experienced life science exec Michael McCullar, as its new president, chief executive and representative director. 19 October 2023
Biotechnology
Singapore-based biotech Hummingbird Bioscience today announced that San Diego, USA-based Endeavor BioMedicines has acquired exclusive worldwide rights to Hummingbird’s antibody-drug conjugate (ADC), HMBD-501. 19 October 2023
Biotechnology
Japanese drugmaker Daiichi Sankyo revealed that it has been ordered by a Texas district court to pay royalties on its antibody-drug conjugate (ADC) to US biotech Seagen. 19 October 2023
Biotechnology
Elevar Therapeutics and Hengrui Pharma have agreed to a global licensing deal giving the former rights to commercialize and develop the checkpoint blocker camrelizumab. 18 October 2023
Biotechnology
Sino-American biotech BeiGene became the first Chinese-origin pharma company to market a programmed cell death protein 1 (PD1) therapy for oncology indications in various global markets, beginning with the European Union. 18 October 2023
Pharmaceutical
Japanese drugmaker Takeda has announced that the Phase III ADMIRE-CD II study of Alofisel (darvadstrocel) in complex Crohn’s perianal fistulas (CPF) failed to meet its primary endpoint of combined remission at 24 weeks, based on topline data. 18 October 2023
Biotechnology
China-headquartered independent biotech MediLink Therapeutics has entered into a strategic research collaboration and worldwide license agreement with Germany’s BioNTech on the development of a next-generation antibody-drug conjugate (ADC) candidate against human epidermal growth factor receptor 3 (HER3). 13 October 2023
Pharmaceutical
New York-based SELLAS Life Sciences is on track to complete enrollment for its Phase III REGAL study of galinpepimut-S (GPS). 13 October 2023
Biotechnology
China’s CARsgen Therapeutics has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with its CAR-GPC3 T-cell therapy. 12 October 2023
Biotechnology
Israel-based cancer and rare diseases drug developer BioLineRx today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia, with the news sending BioLineRx’ shares up 6.7% to $1.60. 12 October 2023
Biotechnology
One big challenge for pharma companies doing cross-border businesses in China and the USA is the respective cybersecurity law imposed by the two countries. 12 October 2023
Pharmaceutical
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
Biotechnology
BioMap today announced a ground-breaking strategic collaboration with French pharma major Sanofi to co-develop cutting-edge artificial intelligence (AI) modules for biologic therapies leveraging BioMap’s AI platform. 11 October 2023
Pharmaceutical
Shares of Chinese high-tech biological enterprise Chongqing Zhifei Biological Products leapt 20% to 58.40 renminbi, on the news that it will to co-promote UK pharma major GSK's shingles vaccine, Shingrix. 9 October 2023
Pharmaceutical
Caught up in the geopolitical tension between China and the West, western pharma multi-national corporations (MNCs) are increasingly cautious about investing in China. 5 October 2023
Biotechnology
Shares of US and UK-based gene therapy company Orchard Therapeutics almost doubled to $16.03 in pre-market activity today, on the news that it has received a takeover offer from mid-size Japanese drugmaker Kyowa Kirin. 5 October 2023
Biotechnology
Following discussions with the US Food and Drug Administration (FDA), Japanese pharm major Takeda said it will be working with the agency towards a voluntary withdrawal of Exkivity (mobocertinib) in the USA. 3 October 2023
Biotechnology
Information from research group GlobalData suggests there is a pressing need for innovation and collaboration in China to address an unmet medical need in Fabry disease. 29 September 2023
Biotechnology
Japanese drugmaker Kyowa Kirin has announced the failure of its Phase III KOUNO-TORI trial. 28 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze